Investigating how MARCH5 affects cell death in acute myeloid leukemia
Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia
This study is looking at a protein called MARCH5 to see how it helps leukemia cells survive, with the hope that blocking it could make current treatments work better for people with acute myeloid leukemia (AML).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11072998 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called MARCH5 in regulating cell death in acute myeloid leukemia (AML). By using advanced techniques like CRISPR-Cas9, the researchers aim to identify how MARCH5 contributes to the survival of leukemia cells and how its inhibition could enhance the effectiveness of existing treatments like venetoclax. The study will explore the mechanisms by which MARCH5 prevents apoptosis, potentially leading to new therapeutic strategies for AML patients. If successful, this research could pave the way for innovative treatments that target MARCH5 to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who may benefit from novel treatment strategies.
Not a fit: Patients with other types of leukemia or those who are not eligible for experimental therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve survival rates for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results in targeting apoptosis pathways in leukemia, suggesting that this approach may be effective.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Lin, Shan — Seattle Children's Hospital
- Study coordinator: Lin, Shan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.